Inconsistent compliance with European Union (EU) rules and added costs attributed to funding and reimbursement are hampering the timely launch of new medical technologies, an industry association said.“These additional requests usually trigger additional cost with no patient safety benefit, reducing the resources that can be made available to research and increasing the so-called ‘time to patient,’” Eucomed told the European Commission.
